Cytek Biosciences earnings release, August 5, 2026

Cytek Biosciences, Inc. (CTKB) · Form 8-K, Item 2.02 · Filed · SEC filing

Cytek Biosciences Reports Second Quarter 2026 Financial Results

FREMONT, Calif., August 5, 2026

(GLOBE NEWSWIRE) – Cytek Biosciences, Inc. (“Cytek Biosciences” or

“Cytek”) (Nasdaq: CTKB), a leading cell analysis solutions company, today reported financial results for the second quarter ended June 30, 2026.

Recent Highlights

“Our second quarter results reflect continued execution against our strategic priorities, exemplified by strong double-digit revenue growth in instruments in the U.S. and in China and ongoing and consistent expansion of our service business,” said Wenbin Jiang, CEO of Cytek Biosciences. “Looking ahead, our priorities remain clear: accelerating adoption of our instrument platforms, including newly launched instruments, expanding recurring revenue business and extending our technology leadership. We believe our investments in products, people, and operations position Cytek well for the remainder of 2026 and the long-term opportunity ahead.”

Second Quarter 2026 Financial Results

Total revenue for the second quarter of 2026 was $48.1 million, a 6% increase compared to the second quarter of 2025. The increase in revenue was driven by strong instrument growth in the U.S. and in China, and continued growth in service.

GAAP gross profit was $28.3 million for the second quarter of

2026, a 19% increase compared to the second quarter of 2025. GAAP gross profit margin was 59% in the second quarter of 2026 compared to 52% in the second quarter of 2025. Adjusted gross profit margin, after adjusting for stock-based compensation expense and amortization of acquisition-related intangibles, was 61% in the second quarter of 2026 compared to 56% in the second quarter of 2025. Excluding the impact of a one-time tariff refund, GAAP and adjusted gross margin in the second quarter of 2026 were 53% and 56%, respectively.

Operating expenses were $39.7 million for the second quarter of 2026, a 15% increase compared to the second quarter of 2025 due to increased research and development, sales and marketing, and general and administrative expenses.

Research and development expenses were $9.7 million for the second quarter of 2026, a 10% increase compared to the second quarter of 2025.

Sales and marketing expenses were

$13.2 million for the second quarter of 2026, a 9% increase compared to the second quarter of 2025.

General and administrative expenses were

$16.8 million for the second quarter of 2026, a 24% increase compared to the second quarter of 2025 due to litigation-related expenses, severance and personnel costs.

Loss from operations in the second quarter of 2026 was $11.4 million compared to loss from operations of $10.6 million in the second quarter of

2025. Net loss in the second quarter of 2026 was $12.2 million compared to a net loss of $5.6 million in the second quarter of 2025.

Adjusted

EBITDA loss in the second quarter of 2026 was $1.5 million compared to positive adjusted EBITDA of $1.3 million in the second quarter of 2025, after adjusting for stock-based compensation expense, foreign currency exchange impacts and a write-off of an investment in an early-stage technology company.

Cash, cash equivalents and marketable securities totaled $262.0 million as of June 30, 2026, compared to $262.2 million as of March 31, 2026, a decrease of $0.2 million.

2026

Outlook

Cytek Biosciences is updating its revenue outlook for the full year 2026 to be in the range of $207 million to $212 million, raising the midpoint by $1 million, assuming no change in current foreign currency exchange rates.

Webcast Information

Cytek will host a conference call to discuss its second quarter 2026 financial results on Wednesday, August 5, 2026, at 1:30 p.m. Pacific Time / 4:30 p.m.

Eastern Time. A webcast of the conference call can be accessed at investors.cytekbio.com.

About Cytek Biosciences, Inc.

Cytek Biosciences (Nasdaq: CTKB) is a leading cell analysis solutions company advancing the next generation of cell analysis tools by delivering high-resolution, high-content and high-sensitivity cell analysis utilizing its patented Full Spectrum Profiling™

(FSP®) technology.

Cytek’s novel approach harnesses the power of information within the entire spectrum of a fluorescent signal to achieve a higher level of multiplexing with precision and sensitivity. Cytek’s platform includes: its core FSP instruments, the Cytek Aurora™, Northern Lights™, Cytek Aurora™

CS and Cytek Aurora™

Evo systems; the Cytek Orion™ reagent cocktail preparation system; the Enhanced Small Particle™

(ESP™) detection technology; the flow cytometers and imaging products under the

Amnis® and Guava® brands; and reagents, software and services to provide a comprehensive and integrated suite of solutions for its customers. Cytek is headquartered in Fremont, California with offices and distribution channels across the globe. More information about the company and its products is available at www.cytekbio.com.

Cytek’s products are for research use only and not for use in diagnostic procedures (other than

Cytek’s Northern

Lights-CLC system and certain reagents, which are available for clinical use only in China and the European Union).

Cytek, Full Spectrum Profiling, FSP, Cytek Aurora, Cytek Borealis, Northern Lights, Enhanced Small Particle, ESP, Cytek Orion, Amnis and Guava are trademarks of Cytek Biosciences, Inc.

In addition to filings with the Securities and Exchange Commission (SEC), press releases, public conference calls and webcasts, Cytek uses its website (www.cytekbio.com), LinkedIn page and X account as channels of distribution for information about the company, its products, planned financial and other announcements, attendance at upcoming investor and industry... (truncated)hannels to disseminate such information in accordance with Regulation FD and other applicable disclosure requirements. Therefore, investors should monitor Cytek’s website, LinkedIn page, and X account in addition to following its SEC filings, news releases, public conference calls and webcasts.

Statement Regarding Use of

Non-GAAP

Financial Information

Cytek has presented certain financial information in accordance with generally accepted accounting principles in the United States (“U.S. GAAP”) and also on a non-GAAP basis for the three-month period ended June 30, 2026 and June 30, 2025. Management believes that non-GAAP financial measures, including

“Adjusted gross profit,” “Adjusted gross profit margin,” “Adjusted EBITDA” and “Adjusted EBITDA excluding investment income,” referenced in this release, taken in conjunction with GAAP financial measures, provide useful information for both management and investors by excluding certain non-cash and other expenses that are not indicative of the company’s core operating results. Management uses non-GAAP measures to compare the company’s performance relative to forecasts and strategic plans and to benchmark the company’s performance externally against competitors.

Non-GAAP information is not prepared under a comprehensive set of accounting rules and should only be used to supplement an understanding of the company’s operating results as reported under U.S. GAAP.

Cytek encourages investors to carefully consider its results under GAAP, as well as its supplemental non-GAAP information and the reconciliation between these presentations, to more fully understand its business. Reconciliations between GAAP and non-GAAP operating results are presented in the accompanying tables of this release.

Financial statements

Income Statement

Three months ended June 30, — (Unaudited) (In thousands, except share and per share data)

Three months ended June 30, – 2026Three months ended June 30, – 2025Six months ended June 30, – 2026Six months ended June 30, – 2025
Revenue, net:Product32,55631,41561,33559,525
Revenue, net:Service15,58414,18730,94027,534
Revenue, net:Total revenue, net48,14045,60292,27587,059
Cost of sales:Product12,88414,92128,80530,450
Cost of sales:Service6,9166,81413,87612,585
Cost of sales:Total cost of sales19,80021,73542,68143,035
Cost of sales:Gross profit28,34023,86749,59444,024
Operating expenses:Research and development9,7418,82619,34518,550
Operating expenses:Sales and marketing13,17412,13424,82024,643
Operating expenses:General and administrative16,82513,53135,29226,429
Operating expenses:Total operating expenses39,74034,49179,45769,622
Operating expenses:Loss from operations-11,400-10,624-29,863-25,598
Other income (expense):Interest expense-281-414-543-705
Other income (expense):Interest income8195551,6061,063
Other income (expense):Other income (expense), net-7813,708-2167,199
Other income (expense):Total other income (expense), net-2433,8498477,557
Other income (expense):Loss before income taxes-11,643-6,775-29,016-18,041
Other income (expense):Provision for (benefit from) income taxes515-1,1922,008-1,056
Other income (expense):Net loss-12,158-5,583-31,024-16,985
Other income (expense):Net loss, basic and diluted-12,158-5,583-31,024-16,985
Other income (expense):Net loss per share, basic-0.09-0.04-0.24-0.13
Other income (expense):Net loss per share, diluted-0.09-0.04-0.24-0.13
Other income (expense):Weighted-average shares used in calculating net loss per share, basic129,460,518126,934,294129,084,814127,632,999
Other income (expense):Weighted-average shares used in calculating net loss per share, diluted129,460,518126,934,294129,084,814127,632,999
Comprehensive loss:Net loss-12,158-5,583-31,024-16,985
Comprehensive loss:Foreign currency translation adjustment, net of tax51760384543
Comprehensive loss:Unrealized loss on marketable securities-147-33-348-98
Comprehensive loss:Net comprehensive loss-11,788-5,013-30,527-17,040

Income Statement

Three Months Ended — (Unaudited) (in thousands)

Three Months Ended – June 30, 2026Three Months Ended – June 30, 2025Six Months Ended – June 30, 2026Six Months Ended – June 30, 2025
GAAP gross profit28,34023,86749,59444,024
Stock based compensation7361,1101,4652,196
Amortization of acquisition-related intangible assets490481984974
Non-GAAP adjusted gross profit29,56625,45852,04347,194
GAAP gross margin59.0%5254.0%51
Non-GAAP adjusted gross margin61.0%5656.0%54
GAAP net income-12,158-5,583-31,024-16,985
Depreciation and amortization2,9852,9885,7975,869
Provision for (benefit from) income taxes515-1,1922,008-1,056
Interest income-819-555-1,606-1,062
Interest expense281414543705
Foreign currency exchange loss (gain)729-1,5931,881-2,871
Stock based compensation5,3396,79110,20013,420
Write-off Investment1,587$—1,587$—
Non-GAAP adjusted EBITDA-1,5411,270-10,614-1,980
Investment income-1,383-2,048-3,012-4,309
Non-GAAP adjusted EBITDA excluding investment income-2,924-778-13,626-6,289

Balance Sheet

June 30, 2026 — (Unaudited) (In thousands, except share and per share data)

June 30, 2026December 31, 2025
Current assets:Cash and cash equivalents73,84690,853
Current assets:Marketable securities188,158170,676
Current assets:Trade accounts receivable, net49,69862,509
Current assets:Inventories52,25148,428
Current assets:Prepaid expenses and other current assets13,97819,530
Current assets:Total current assets377,931391,996
Current assets:Property and equipment, net20,80118,009
Current assets:Operating lease right-of-use assets10,96211,315
Current assets:Goodwill16,69016,697
Current assets:Intangible assets, net14,86516,821
Current assets:Other noncurrent assets5,6856,704
Current assets:Total assets446,934461,542
Current liabilities:Trade accounts payable8,4086,410
Current liabilities:Legal settlement liability, current2,3532,495
Current liabilities:Accrued expenses23,85523,417
Current liabilities:Other current liabilities20,51316,978
Current liabilities:Deferred revenue, current29,20628,504
Current liabilities:Total current liabilities84,33577,804
Current liabilities:Legal settlement liability, noncurrent6,3686,786
Current liabilities:Deferred revenue, noncurrent18,05818,339
Current liabilities:Operating lease liability, noncurrent13,51714,042
Current liabilities:Long-term debt246525
Current liabilities:Other noncurrent liabilities2,4562,307
Current liabilities:Total liabilities124,980119,803
Stockholders’ equity:Common stock, $0.001 par value; 1,000,000,000 authorized shares as of June 30, 2026 and December 31, 2025, respectively; 129,982,753 and 128,550,136 issued and outstanding shares as of June 30, 2026 and December 31, 2025, respectively130129
Stockholders’ equity:Additional paid-in capital451,846441,107
Stockholders’ equity:Accumulated deficit-132,761-101,738
Stockholders’ equity:Accumulated other comprehensive income2,7392,241
Full release

Forward-Looking Statements

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 as contained in Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, which are subject to the “safe harbor” created by those sections. All statements, other than statements of historical facts, may be forward-looking statements. Forward-looking statements generally can be identified by the use of forward-looking terminology such as “may,” “might,” “will,” “should,” “expect,” “plan,” “anticipate,” “could,” “intend,”

“target,” “project,” “contemplate,” “believe,” “estimate,” “predict,” “potential” or “continue” or the negatives of these terms or variations of them or similar terminology, but the absence of these words does not mean that a statement is not forward-looking. These forward-looking statements include, without limitation, statements regarding Cytek’s business strategies, market opportunities, product plans and expectations, and continued investment in its products, people, and infrastructure; Cytek’s expanding installed base and future recurring revenue growth in its service and reagent businesses; and Cytek’s future financial performance, including its outlook for fiscal year 2026 and expectations for 2026 total revenue. These statements are based on management’s current expectations, forecasts, beliefs, assumptions and information currently available to management. These statements also deal with future events and involve known and unknown risks, uncertainties and other factors that may cause actual results, performance or achievements to be materially different from the information expressed or implied by these forward-looking statements. In addition, new risks and uncertainties emerge from time to time, and it is not possible for us to predict all risks and uncertainties that could have an impact on the forward-looking statements. Factors that could cause actual results to differ materially include global geopolitical, economic and market conditions;

Cytek’s ability to manage the impacts of recent and future export controls and licensing requirements, tariffs and NIH funding policies on its business; Cytek’s ability to evaluate its prospects for future viability and predict future performance; Cytek’s ability to accurately forecast customer demand and adoption of its products; Cytek’s ability to recognize the anticipated benefits of collaborations; Cytek’s dependence on certain sole and single source suppliers; competition; market acceptance of Cytek’s current and potential products; Cytek’s ability to manage the growth and complexity of its organization, maintain relationships with customers and suppliers and hire and retain key employees; Cytek’s ability to manufacture its products in high-quality commercial quantities successfully and consistently to meet demand; Cytek’s ability to increase penetration in its existing markets and expand into adjacent markets;

Cytek’s ability to secure additional distributors or maintain good relationships with its existing distributors; Cytek’s ability to successfully develop and introduce new products; Cytek’s ability to maintain, protect and enhance its intellectual property; Cytek’s ability to continue to stay in compliance with its material contractual obligations, applicable laws and regulations; and foreign currency exchange impacts. You should refer to the section titled “Risk

Factors” set forth in Cytek’s most recent Quarterly Report on Form

10-Q filed with the SEC on May 7, 2026, Cytek’s Quarterly Report on Form

10-Q to be filed with the SEC on or about the date hereof and other filings Cytek makes with the SEC from time to time for a discussion of important factors that may cause actual results to differ materially from those expressed or implied by

Cytek’s forward-looking statements. Although Cytek believes that the expectations reflected in the forward-looking statements are reasonable, it cannot provide any assurance that these expectations will prove to be correct nor can it guarantee... (truncated)and events and circumstances reflected in the forward-looking statements will be achieved or occur. The forward-looking statements in this press release are applicable only as of the date on which they are made, and Cytek does not assume any obligation to update any forward-looking statements provided to reflect any change in its expectations or any change in events, conditions, or circumstances on which any such statement is based, except as required by law. These forward-looking statements should not be relied upon as representing Cytek’s views as of any date subsequent to the date of this press release. Information contained on, or that is referenced or can be accessed through, our website does not constitute part of this document and inclusions of any website addresses herein are inactive textual references only.

Media Contact:

Stephanie Olsen

Lages & Associates

(949)

453-8080 stephanie@lages.com

Investor Contact:

Mark Meehan

Cytek Biosciences mmeehan@cytekbio.com

Cytek Biosciences, Inc.

Consolidated Balance Sheets

(Unaudited)

Cytek Biosciences, Inc.

Consolidated Statements of Operations and Comprehensive Loss

(Unaudited)

Cytek Biosciences, Inc.

Reconciliation of GAAP to

Non-GAAP

Measures

(Unaudited)

From SEC EDGAR. Analysis by Pear Digitals from the filing alone. Not investment advice. · Cytek Biosciences earnings · Latest earnings · Markdown

Screener

Plans

Premium and Pro coming soon.

Log in

New here?

Join the waitlist

Pear FMV opens to everyone soon. We'll email you when it does.